| dc.contributor.author | Camci, C. | |
| dc.contributor.author | Sencan, O. | |
| dc.contributor.author | Yilmaz, U. | |
| dc.contributor.author | Zengin, N. | |
| dc.contributor.author | Buyukunal, E. | |
| dc.contributor.author | Buyukberber, S. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Yalcin, S. | |
| dc.contributor.author | Uslu, R. | |
| dc.contributor.author | Dane, F. | |
| dc.date.accessioned | 2021-03-04T19:03:39Z | |
| dc.date.available | 2021-03-04T19:03:39Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., "A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer", JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_8de1584c-3ac6-4141-b45c-8a025ed295d3 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/95894 | |
| dc.identifier.uri | https://doi.org/10.1200/jco.2011.29.4_suppl.474 | |
| dc.language.iso | eng | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.title | A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 29 | |
| dc.identifier.issue | 4 | |
| dc.contributor.firstauthorID | 199441 | |
